Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy

Summary:

It is generally accepted that growth factors play an important role in the pathogenesis of proliferative diabetic retinopathy. Since platelet-derived growth factor AB (PDGF AB) is known to be involved in many angiogenetic and proliferative processes, it was the aim of our study to elucidate the role of PDGF AB in the angiogenetic process in proliferative diabetic retinopathy. We measured PDGF AB concentrations in the vitreous of 23 patients with proliferative diabetic retinopathy, 4 of them with additional rubeosis iridis as an indicator of very high vasoproliferative activity. Control measurements were done in 19 patients without diabetic or ischemic eye diseases and also in 4 non-diabetic patients with ischemic proliferative retinopathy with rubeosis iridis. To exclude PDGF remnants in the vitreous due to vitreous bleeding we additionally measured platelet factor 4 concentrations as a stable marker of activated thrombocytes in the vitreous. Results: Significantly elevated concentrations of PDGF AB were found in the vitreous of patients with proliferative diabetic retinopathy, with higher levels in individuals with additional rubeosis iridis compared to controls. However, concentrations of PDGF AB were also elevated in ischemic non-diabetic retinopathy, supporting the concept that ischemia might be a strong stimulator of growth factor production in the retina. Platelet factor 4 was not detectable in any of the vitreous samples included in the study.

In summary, our results indicate that the growth factor PDGF plays an important role in the pathogenesis of proliferative diabetic retinopathy, probably in synergistic action with other growth factors like IGF I, IGF II, VEGF and TNFα.

Proliferative diabetic retinopathy - growth factors - PDGF

References

• 1 Ferns G A, Raines E W, Sprügel K H, Motani A S, Reidy M A, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF.  Science. 253 1129-1132 1991; 
• 2 Flyvbjerg A. Growth factors and diabetic complications.  Diabet. Med.. 7 387-399 1990; 
• 3 Hayek A, Culler F L, Beattie G M, Lopez A D, Cuevas P, Baird A. An in vivo model for study of the angiogenic effects of basic fibroblast growth factor.  Biochem. Biophys. Res. Commun.. 147 876-880 1987; 
• 4 Heldin C-H, Westermark B. Platelet-derived growth factor: mechanism of action and possible in vivo function.  Cell Regulation. 1 555-566 1990; 
• 5 Inaba T, Ishibashi S, Gotoda T, Kawamura M, Morino N, Nojima Y, Kawakami M, Yazaki Y, Yamada N. Enhanced expression of platelet-derived growth factor-β receptor by high glucose. Involvement of platelet-derived growth factor in diabetic angiopathy.  Diabetes. 45 507-512 1996; 
• 6 Koyama N, Watanabe S, Tezuka M, Morisaki N, Saito Y, Yoshida S. Migratory and proliferative effect of platelet-derived growth factor in rabbit retinal endothelial cells: evidence of an autocrine pathway of platelet-derived growth factor.  J. Cell. Physiol.. 158 1-6 1996; 
• 7 Merimee T J. Diabetic retinopathy, a synthesis of perspectives.  N. Engl. J. Med.. 322 978-983 1990; 
• 8 Meyer-Schwickerath R, Pfeiffer A, Blum W F, Freyberger H, Klein M, Losche C, Rollmann R, Schatz H. Vitreous levels of the insulin-like growth factors I and II and the insulin-like growth factor binding protein 2 and 3, increase in neovascular eye diseases. Studies in nondiabetic and diabetic subjects.  J. Clin. Invest.. 92 2620-2625 1993; 
• 9 Nagaoka J, Trapnell B C, Cystal R G. Upregulation of platelet-derived growth factor-A and -B gene expression in alveolar macrophages of individuals with idiopathic pulmonary fibrosis.  J. Clin. Invest.. 85 2023-2027 1990; 
• 10 Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retina cells is a common factor in neovasculariuing ocular diseases.  Lab. Invest.. 72 638-645 1995; 
• 11 Pfeiffer A, Middelberg-Bisping K, Drewes C, Schatz H. Elevated plasma levels of transforming growth factor-β in NIDDM.  Diabetes Care. 19 1113-1117 1996; 
• 12 Pfeiffer A, Schatz H. Diabetic microvascular complications and growth factors.  Exp. Clin. Endocrinol. Diabetes. 103 7-14 1995; 
• 13 Robbins S G, Mixon R N, Wilson D J, Hart C E, Robertson J E, Westra I, Planck S R, Rosenbaum J T. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases.  Invest. Ophthalmol. Vis. Sci.. 35 3649-3663 1994; 
• 14 Report of the National Commission on Diabetes to the Congress of the United States. DHEW publication No. (NIH) 76-1018.
• 15 Ross R. Mechanisms of atherosclerosis - a review.  Adv. Nephrol. Necker Hosp.. 19 79-86 1990; 
• 16 Ross R, Raines E W, Bowen-Pope D F. The biology of platelet-derived growth factor.  Cell. 46 155-169 1986;